Biomarkers for predicting clinical responses to HDAC inhibitors

Cancer Letters

Volumn 280, Issue 2, 2009, Pages 177-183

  Stimson, Lindsay ^a   La Thangue, Nicholas B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; Cancer; Clinical; HDAC; Inhibitor

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ANGIOPOIETIN 1; AZACITIDINE; BORTEZOMIB; CISPLATIN; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; FK 2228; GEMCITABINE; HEAT SHOCK PROTEIN 90; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; ITF 2537; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PACLITAXEL; PANOBINOSTAT; R 306465; ROMIDEPSIN; TANESPIMYCIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GENE IDENTIFICATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOLID TUMOR;

EID: 67349157687     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.016     Document Type: Review

References (46)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Richardson P.G., Mitsiades C., Schlossman R., Ghobrial I., Hideshima T., Munshi N., and Andersion J.C. Bortezomib in the front-line treatment of multiple myeloma. Expert Review Anti-Cancer Therapeutics 8 7 (2008) 1053-1072
3. Grothey A., and Ellis L.M. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer Journal 14 3 (2008) 170-177
4. Lesko L.J., and Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Reviews Drug Discovery 3 9 (2003) 763-769
5. http://www.fda.gov.
6. Glozak M.A., Sengupta N., Zhang X., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
7. Inche A.G., and La Thangue N.B. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discovery Today 11 (2006) 97-109
8. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics 2 (2003) 151-163
9. Johnstone R.W., and Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 4 (2003) 13-18
10. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringapure V., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., Bailey C., Joseph M., Libermann T.A., Richon V.M., Marks P.A., and Anderson K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences 101 (2004) 540-545
11. Park J.H., Yung Y., Kim T.Y., Kim S.G., Jong H.S., Lee J.W., Kim D.K., Lee J.S., Kim N.K., Kim T.Y., and Bang Y.J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumour proliferation. Clinical Cancer Research 10 (2004) 5271-5281
12. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., and Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression independent of histone deacetylase 1. Cell Death and Differentiation 12 (2005) 395-404
13. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., and Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. The EMBO Journal 22 (2003) 1168-1179
14. Boyault C., Gilquin B., Zhang Y., Rybin V., Garmen E., Meyer-Klaucke W., Matthias P., Muller C.W., and Khochbin S. HDAC6-p97/VCP controlled polyubiquitin chain turnover. The EMBO Journal 25 (2006) 3357-3366
15. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., and Olsen E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110 (2002) 479-488
16. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., McAnally J., pomajzl C., Shelton J.M., Richardson J.A., Karsenty G., and Olsen E.N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119 (2004) 555-566
17. Arnold M.A., Kim Y., Czubryt M.P., Phan D., McAnally J., Qi X., Shelton J.M., Richardson J.A., Bassel-Duby R., and Olson E.N. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Developmental Cell 12 (2007) 377-389
18. Dequiedt E., Kasler H., Fischle W., Kiermer V., Weinstein M., Herndier B.G., and Verdin E. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18 (2003) 687-698
19. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 6749 (1999) 188-193
20. Glaser K.B., et al. HDAC inhibitors: clinical update and mechanism-based potential. Biochemical Pharmacology 74 5 (2007) 659-671
21. Grant S., Easley C., and Kirkpatrick P. Vorinostat. Nature Reviews Drug Discovery 6 (2007) 21-22
22. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.H., Dalmoush L., Kingma D.M., Turner M.L., Altemus R., and Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98 (2001) 2865-2868
23. Piekarz R.L., et al. Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. ASCO Annual Meeting Proceedings. Journal of Clinical Oncology (2004) 3028
24. Piekarz R.L. Histone deacetylase inhibitors in peripheral and cutaneous T-cell lymphoma. Clinical Advances in Hematologic Malignancies 4 (2007) 1-3
25. Younes A., et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 25 18S (2007) 8000
26. Bociek R.G., et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). ASCO Annual Meeting Proceedings. Journal of Clinical Oncology 20 (2008) 8507
27. Arnold N.B., Arkus N., Gunn J., and Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clinical Cancer Research 13 (2007) 18-26
28. Dowdy S.C., Jiang S., Zhou X.C., Hou X., Jin F., Podratz K.C., and W Jiang S. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Molecular Cancer Therapeutics 5 (2006) 767-2776
29. Rikiishi H., Shinohara F., Sato T., Sato Y., Suzuki M., and Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. International Journal of Oncology 30 (2007) 1181-1188
30. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Research 63 (2003) 7291-7300
31. Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P., and Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demothoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukaemic cells. Cancer Research 63 (2003) 8420-8427
32. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner Jr. K., Pal A., Bornmann W.G., Chiao P.J., Huang P., Xiong H., Abbruzzese J.L., and McConkey D.J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Research 66 (2006) 3773-3781
33. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silences in cancer. Nature Genetics 21 (1999) 103-107
34. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., and Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical Cancer Research 14 6 (2008) 1669-1677
35. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., and Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British Journal of Cancer 98 3 (2008) 604-610
36. Khan O., and La Thangue N.B. Drug insight: histone deacetylase-based therapies for cutaneous T-cell lymphomas. Nature Clinical Practise Oncology 5 12 (2008) 714-726
37. Marquard L., Gjerdrum L.M., Christensen Ib.J., Jensen P.B., Sehested M., and Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53 3 (2008) 267-277
38. Ellis L., Pan Y., Smith G.K., George D.J., McCormack C., Williams-Truax R., Mita M., Beck J., Burris H., Ryan G., Atadja P., Butterfoss D., Dugan M., Culver K., Johnstone R.W., and Prince H.M. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research 14 14 (2008) 4500-4510
39. Miyanaga A., Gemma A., Noro R., Kataoka K., Matsuda K., Nara M., Okano T., Seike M., Yoshimura A., Kawakami A., Uesaka H., Nakae H., and Kudoh S. Antitumour activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Molecular Cancer Therapeutics 7 7 (2008) 1923-1930
40. Dejligbjerg M., Grausland M., Christensen I.J., Tjornelund J., Buhl Jensen P., and Sehested M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomarkers 4 2 (2008) 101-109
41. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., and Brown R. Pharmacodynamic response and inhibition of growth of human tumour xenografts by the novel histone deacetylase inhibitor PXD101. Molecular Cancer Therapeutics 2 (2003) 721-728
42. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., Randolph S.S., Hardwick J.S., Reilly J.F., Chen C., Ricker J.L., Secrist J.P., Richon V.M., Frankel S.R., and Kantarjian H.M. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukaemias and myelodysplastic syndromes. Blood 111 3 (2008) 1060-1066
43. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Rasmussen A., Ooi C.E., Buhl-Jensen P., Brown R., Jeffry Evans T.R., and De Bono J.S. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advance solid tumours. Clinical Cancer Research 14 3 (2008) 804-810
44. Arts J., Angibaud P., Marien A., Floren W., Janssens B., King P., van Dun J., Janssen L., Geerts T., Tuman R.W., Johnson D.L., Andries L., Jung M., Janicot M., and van Emelen K. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer 97 (2007) 1344-1353
45. de Bono J.S., Kristeleit R., Tolcher A., Fong P., Pacey S., Karavasilis V., Mita M., Shaw H., Workman P., Kaye S., Rowinsky E.K., Aherne W., Atadja P., Scott J.W., and Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advance solid tumours. Clinical Cancer Research 14 20 (2008) 6663-6673
46. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., Bernards R., and La Thangue N.B. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15 (2009) 57-66